Terms: = Leukemia AND IL2, IL-2, 3558, ENSG00000109471, P60568 AND Treatment
655 results:
1. Ponatinib and STAT5 Inhibitor Pimozide Combined Synergistic treatment Applications Potentially Overcome Drug Resistance via Regulating the Cytokine Expressional Network in Chronic Myeloid leukemia Cells.
Tezcanli Kaymaz B; Gumus N; Celik B; Alcitepe İ; Biray Avci C; Aktan C
J Interferon Cytokine Res; 2024 Apr; 44(4):178-189. PubMed ID: 38579140
[TBL] [Abstract] [Full Text] [Related]
2. Discovery of 5-aminopyrido[2,3-d]pyrimidin-7(8H)-one derivatives as new hematopoietic progenitor kinase 1 (HPK1) inhibitors.
Qiu X; Liu R; Ling H; Zhou Y; Ren X; Zhou F; Zhang J; Huang W; Wang Z; Ding K
Eur J Med Chem; 2024 Apr; 269():116310. PubMed ID: 38479166
[TBL] [Abstract] [Full Text] [Related]
3. [Immune Reconstitution after BTKi treatment in Chronic Lymphocytic leukemia].
Wang YL; Tang PX; Chen KL; Guo GY; Long JL; Zou YQ; Liang HY; Xu ZS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):1-5. PubMed ID: 38387891
[TBL] [Abstract] [Full Text] [Related]
4. Development of Innate-Immune-Cell-Based Immunotherapy for Adult T-Cell leukemia-Lymphoma.
Nakashima M; Tanaka Y; Okamura H; Kato T; Imaizumi Y; Nagai K; Miyazaki Y; Murota H
Cells; 2024 Jan; 13(2):. PubMed ID: 38247820
[TBL] [Abstract] [Full Text] [Related]
5. Higher Expression of Human Endogenous Retrovirus-K was Observed in Peripheral B Lymphocytes of leukemia and Lymphoma Patients.
Li T; Qian K; Han J; Liu Y; Jia L; Wang X; Li T; Zhang B; Li J; Li H; Dou L; Li L
AIDS Res Hum Retroviruses; 2024 Apr; 40(4):268-279. PubMed ID: 38009220
[TBL] [Abstract] [Full Text] [Related]
6. Adverse events and efficacy of second-round CAR-T cell therapy in relapsed pediatric B-ALL.
Ji Q; Wu X; Zhang Y; Zeng L; Dong Y; Liu R; Li B; Bai Z; Hu S; Lu J; Wu S
Eur J Haematol; 2024 Jan; 112(1):75-82. PubMed ID: 37649264
[TBL] [Abstract] [Full Text] [Related]
7. [Adult T-cell leukemia/lymphoma with multiple intracranial masses and CMV and HHV-6 reactivation at initial presentation].
Hori T; Yasui S; Hosoki M; Yamagami H; Otoda T; Yuasa T; Aihara KI; Takishita M; Abe M; Nakamura S
Rinsho Ketsueki; 2023; 64(4):283-289. PubMed ID: 37121773
[TBL] [Abstract] [Full Text] [Related]
8. JAK1 Pseudokinase V666G Mutant Dominantly Impairs JAK3 Phosphorylation and il-2 Signaling.
Grant AH; Rodriguez AC; Rodriguez Moncivais OJ; Sun S; Li L; Mohl JE; Leung MY; Kirken RA; Rodriguez G
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047778
[TBL] [Abstract] [Full Text] [Related]
9. BTLA dysregulation correlates with poor outcome and diminished T cell-mediated antitumor responses in chronic lymphocytic leukemia.
Sordo-Bahamonde C; Lorenzo-Herrero S; Martínez-Pérez A; Gonzalez-Rodriguez AP; Payer ÁR; González-García E; Aguilar-García C; González-Rodríguez S; López-Soto A; García-Torre A; Gonzalez S
Cancer Immunol Immunother; 2023 Jul; 72(7):2529-2539. PubMed ID: 37041226
[TBL] [Abstract] [Full Text] [Related]
10. Identification of Hub Genes Associated with Resistance to Prednisolone in Acute Lymphoblastic leukemia Based on Weighted Gene Co-expression Network Analysis.
Nekoeian S; Ferdowsian S; Asgari Y; Azizi Z
Mol Biotechnol; 2023 Nov; 65(11):1913-1922. PubMed ID: 36877306
[TBL] [Abstract] [Full Text] [Related]
11. Regulatory T Cell Amelioration of Graft-versus-Host Disease following Allogeneic/Xenogeneic Hematopoietic Stem Cell Transplantation Using Mobilized Mouse and Human Peripheral Blood Donors.
Barreras H; Copsel SN; Bader CS; Ding Y; Wolf D; Cash C; Stacey CJ; Benjamin C; Seavey MM; Wolf J; Jasuja RR; Pfeiffer B; Hill GR; Komanduri KV; Jurecic R; Malek TR; Levy RB
Transplant Cell Ther; 2023 May; 29(5):341.e1-341.e9. PubMed ID: 36804930
[TBL] [Abstract] [Full Text] [Related]
12. Repurposing fluoxetine to treat lymphocytic leukemia: Apoptosis induction, sigma-1 receptor upregulation, inhibition of il-2 cytokine production, and autophagy induction.
Chomchoei C; Brimson JM; Brimson S
Expert Opin Ther Targets; 2022 Dec; 26(12):1087-1097. PubMed ID: 36620917
[TBL] [Abstract] [Full Text] [Related]
13. Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib.
Häselbarth L; Karow A; Mentz K; Böttcher M; Roche-Lancaster O; Krumbholz M; Jitschin R; Mougiakakos D; Metzler M
Cancer Immunol Immunother; 2023 Jun; 72(6):1661-1672. PubMed ID: 36602564
[TBL] [Abstract] [Full Text] [Related]
14. Cord blood stem cell-generated KIR
Dizaji Asl K; Rafat A; Mazloumi Z; Valipour B; Movassaghpour A; Talebi M; Mahdavi M; Tayefi Nasrabadi H; Nozad Charoudeh H
Hum Immunol; 2023 Feb; 84(2):98-105. PubMed ID: 36396515
[TBL] [Abstract] [Full Text] [Related]
15. IL-7: Comprehensive review.
Winer H; Rodrigues GOL; Hixon JA; Aiello FB; Hsu TC; Wachter BT; Li W; Durum SK
Cytokine; 2022 Dec; 160():156049. PubMed ID: 36201890
[TBL] [Abstract] [Full Text] [Related]
16. Bioactivity of Exosomes Derived from Trained Natural Killer Cells versus Non-Trained One: More Functional and Antitumor Activity.
Mohammadi F; Hashemi ZS; Forooshani RS; Alizadeh S
Biomed Res Int; 2022; 2022():5396628. PubMed ID: 36060136
[TBL] [Abstract] [Full Text] [Related]
17. [Clinical Safety of NK Cell in the Prevention of leukemia Relapse Post-transplantation and in treatment of the Elderly leukemia Patients].
Liu J; Zheng XL; Xue M; Zhu L; Ding L; Han DM; Yan HM; Li S; Ma JD; Tan XT; Zhou JX; Guo ZK; Wang HX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Aug; 30(4):1267-1271. PubMed ID: 35981396
[TBL] [Abstract] [Full Text] [Related]
18. il-2 and Zoledronic Acid Therapy Restores the
Mylabathula PL; Diak DM; Baker FL; Niemiro GM; Markofski MM; Crucian BE; Katsanis E; Simpson RJ
Front Biosci (Landmark Ed); 2022 Jul; 27(7):215. PubMed ID: 35866402
[TBL] [Abstract] [Full Text] [Related]
19. Retention of Donor T Cells in Lymphohematopoietic Tissue and Augmentation of Tissue PD-L1 Protection for Prevention of GVHD While Preserving GVL Activity.
Song Q; Nasri U; Nakamura R; Martin PJ; Zeng D
Front Immunol; 2022; 13():907673. PubMed ID: 35677056
[TBL] [Abstract] [Full Text] [Related]
20. Autologous hematopoietic stem cell transplantation followed by interleukin-2 for adult acute myeloid leukemia patients with favorable or intermediate risk after complete remission.
Zeng Q; Xiang B; Liu Z
Ann Hematol; 2022 Aug; 101(8):1711-1718. PubMed ID: 35570208
[TBL] [Abstract] [Full Text] [Related]
[Next]
